



8<sup>th</sup> August 2014

## SHARE PLACEMENT UPDATE

SomnoMed Limited ("SOM"- ASX) today announced it had allotted 3.43 million new ordinary shares, pursuant to a placement announced on 25<sup>th</sup> July 2014 at \$1.50 per share.

"We are delighted with the confidence investors have shown in the future of our Company," commented Dr Peter Neustadt, Executive Chairman of SomnoMed Limited.

The Company's 2014 Share Purchase Plan Offer, providing all shareholders the opportunity to invest in the Company at the same price as the placement, will close on 15<sup>th</sup> August 2014.

As previously announced, in addition to the above, a further 270,000 shares will be issued to the Chairman and other Directors of the Company at the same price, subject to shareholder approval to be obtained at the Company's 2014 AGM.

**Contact:** Dr. Peter Neustadt – Executive Chairman and CEO, SomnoMed Limited

Ph +61 2 9467 0400 or +61 (0) 414 566 592 - mobile

### **About SomnoMed**

SomnoMed is a public company providing diagnostic and treatment solutions for Sleep-related Breathing Disorders including obstructive sleep apnea, snoring and bruxism. SomnoMed was commercialized on the basis of extensive clinical research. Supporting independent clinical research, continuous innovation and instituting medical manufacturing standards has resulted in SomnoDent<sup>®</sup> becoming the state-of-the-art and clinically proven medical oral appliance therapy for obstructive sleep apnea. SomnoDent<sup>®</sup> is the most comfortable and effective design and treatment solution for over 175,000 patients in 24 countries.

For additional information, visit SomnoMed at <http://www.somnomed.com.au>